

Table SI. Lichenoid reactions occurring across several classes of biologic agents

Drug class	Diseases treated in cited cases	Lichenoid reaction observed
TNF alpha antibodies Etanercept (7) CT P-13, infliximab biosimilar (6) Adalimumab (8)	Rheumatoid arthritis, inflammatory bowel disease, psoriasis, psoriatic arthritis	Lichen striatus, lichenoid drug reaction
Anti-CD20 antibody Rituximab (9)	Follicular lymphoma	Lichenoid mucositis
CTLA-4 antibodies Ipilimumab (12) Tremelimumab (4)	Metastatic melanoma, renal cell carcinoma	Lichenoid reactions varying from minimally scaly papules to plaques
Anti-PD1 antibodies (10, 11) Nivolumab (12) Pembrolizumab	Metastatic lung adenocarcinoma, metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, multiple myeloma, glioblastoma multiforme, breast cancer	Lichenoid mucocutaneous eruptions, oral ulcers associated with lichenoid reaction, lichenoid keratoses
Anti-PD-L1 antibodies Avelumab (13) Atezolizumab (11)	Merkel cell carcinoma, renal cell carcinoma	Lichen planus like keratoses, cutaneous lichenoid reaction
IL-17A antibody Secukinumab(14)	Psoriasis	Oral lichenoid reaction
CCR4 antibody Mogamulizumab (5)	Cutaneous T cell lymphoma,	Granulomatous drug eruption